title: Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes.
abstract: The effects and kinetics of oral glibenclamide (Gb) and glipizide (Gz) were studied in Caucasian and Chinese patients (ten in each group) with type-2 diabetes. In randomised order, 2.5 mg Gb, 2.5 mg Gz or placebo was given orally before the administration of 75 g oral glucose. Concentrations of insulin and proinsulin were determined using radioimmunoassay (RIA) without cross-reactivities, and sulphonylurea concentrations were determined using high-performance liquid chromatography (HPLC). There were no significant interethnic differences in Gb or Gz effects whether on glucose, insulin or proinsulin/insulin ratio at any time point. Following Gz, however, Chinese patients had greater increments of serum proinsulin at 10-30 min compared with Caucasians. Apart from the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of Gz being higher among the Chinese, no significant interethnic differences in pharmacokinetics were found. It appears that the same dosage principles could be used for Caucasian and Chinese patients with type-2 diabetes when Gb or Gz are prescribed.
authors.affiliation: Department of Endocrinology, Lund University, Malmö University Hospital, Sweden. anders.joensson@ryhov.ltjkpg.se
authors.forename: A
authors.initials: A
authors.lastname: Jönsson
authors.forename: J C
authors.initials: JC
authors.lastname: Chan
authors.forename: T
authors.initials: T
authors.lastname: Rydberg
authors.forename: S
authors.initials: S
authors.lastname: Vaaler
authors.forename: B
authors.initials: B
authors.lastname: Hallengren
authors.forename: C S
authors.initials: CS
authors.lastname: Cockram
authors.forename: J A
authors.initials: JA
authors.lastname: Critchley
authors.forename: A
authors.initials: A
authors.lastname: Melander
mesh_terms: D000328:Adult; D000368:Aged; D044466:Asian People; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D005913:Glipizide / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D005951:Glucose Tolerance Test; D005905:Glyburide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D011384:Proinsulin / Q000097:blood; D044465:White People
chemical_list: D001786:Blood Glucose; D005913:Glipizide; D005905:Glyburide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D011384:Proinsulin